2. Search Result
Search Result
Results for "

Metastatic HER2-positive breast cancer

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

7

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99030
    Margetuximab

    		EGFR Cancer
    Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
    Margetuximab
  • HY-P9912
    Pertuzumab
    5+ Cited Publications

    		 EGFR Cancer
    Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
    Pertuzumab
  • HY-P9912A
    Pertuzumab (anti-HER2)

    		EGFR Cancer
    Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
    Pertuzumab (anti-HER2)
  • HY-P99437
    Anbenitamab
    1 Publications Verification

    KN-026

    		 EGFR Cancer
    Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .
    Anbenitamab
  • HY-P9907
    Trastuzumab
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human HER2, Humanized Antibody

    		 Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody Cancer
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab
  • HY-P9907A
    Trastuzumab (anti-HER2)
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human HER2, Humanized Antibody (PBS)

    		 ADC Antibody EGFR Cancer
    Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-P99630
    Gancotamab

    MM-302

    		 EGFR Cancer
    Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
    Gancotamab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: